Hirsutes II: Treatment

Australasian Journal of Dermatology

Volumn 39, Issue 3, 1998, Pages 151-157

  Young, Richard ^a   Sinclair, Rod ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anti androgens; Finasteride; Flutamide; Gonadotrophin releasing hormone agonists; Hirsutism; Laser; Oral contraceptive; Spironolactone

Indexed keywords

BUSERELIN; CYPROTERONE ACETATE; DIANE; FLUTAMIDE; GONADORELIN AGONIST; PREDNISOLONE; SPIRONOLACTONE;

BLEACHING; CORTICOSTEROID THERAPY; HIRSUTISM; HORMONE INHIBITION; HUMAN; LASER; REVIEW; TREATMENT PLANNING;

EID: 0031830296     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-0960.1998.tb01271.x     Document Type: Review

References (66)

1. Hughes CL. Hirsutes. In: Olsen EA (ed.) Disorders of Hair Growth, Diagnosis and Treatment, 1st edn. New York: McGraw-Hill, 1994; 337-51.
2. Grossman DC, Dierickx C, Farinelli W, Flotte T, Anderson RR. Damage to hair follicles by normal-mode ruby laser pulses. J. Am. Acad. Dermatol. 1996; 35: 889-94.
3. Zachariae H, Bjerring P, Lybecker H. Laser depilation using a free-running, long pulse ruby laser: A preliminary investigation. Australas. J. Dermatol. 1997; 38 (Suppl. 2): S52.
4. Badewitz-Dodd LM (ed.). 1996 MIMS Annual, 20th edn. St Leonards, NSW: Tien Wah Press, 1996; 353-69.
5. Carr BR, Breslau NA, Givens C. Oral contraceptive pills, gonadotrophin-releasing hormone agonists, or use in combination for treatment for treatment of hirsutism: A clinical research centre study. J. Clin. Endocrinol. Metab. 1995; 80: 1169-78.
6. Falsetti L, Pasinetti E, Ceruti D. Gonadotrophin releasing hormone agonist in hirsutism. Acta Eur. Fert. 1994; 25: 303-6.
7. Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotrophin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil. Steril. 1994; 61: 817-22.
8. Weisberg E. Choosing an oral contraceptive. Mod. Med. Aust. 1997; 51: 18-26.
9. Cullberg G, Hamberger L, Mattsson L. Low dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome. Acta Obstet. Gynaecol. Scand. 1985; 64: 195-202.
10. Dewis P, Petsos P, Newman N. The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol. J. Clin. Endocrinol. Metab. 1985; 22: 29-36.
11. Azziz R, Ochoa TM, Bradley B. Leuprolide and estrogen vs oral contraceptive pills for the treatment of hirsutism: A prospective randomised study. J. Clin. Endocrinol. Metab. 1995; 80: 3403-5.
12. Ciotta L, Cianci A, Marletta E. Treatment of hirsutism with flutamide and low dose oral contraceptive in polycystic ovarian disease patients. Fertil. Steril. 1994; 62: 1129-35.
13. Heiner JS, Greendale GA, Kawakami AK. Comparison of a gonadotrophin releasing agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J. Clin. Endocrinol. Metab. 1995; 80: 3412-18.
14. Carmina E, Janni A, Lobo RA. Physiological oestrogen replacement may enhance the effectiveness of the gonadotrophin releasing hormone agonist in the treatment of hirsutism. J. Clin. Endocrinol. Metab. 1994; 78: 126-30.
15. Elkind-Hirsch KE, Anania C, Mack M. Combination gonadotrophin releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism. Fertil. Steril. 1995; 63: 970-8.
16. Moghetti P, Castello R, Magnani CM. Clinical and hormonal effects of the 5-α reductase inhibitor finasteride in idiopathic hirsutism. J. Clin. Endocrinol. Metab. 1994; 79: 1115-21.
17. Corson SL. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. Acta Obstet. Gynaecol. Scand. 1990; 152: S25-31.
18. Janaud A, Rouffy J, Upmalis D. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet. Gynaecol. Scand. 1992; 71: S33-8.
19. Darney P. Safety and efficacy of a triphasic oral contraceptive containing desonorgestrel: Results of three multicentre trials. Contraception 1993; 48: 323-37.
20. Hawley W, Nuovo J, DeNeef CP. Do oral contraceptive agents affect the risk of breast cancer? A meta-analysis of the case-control reports. J. Am. Board Fam. Pract. 1993; 6: 123-35.
21. Romieu I, Berlin J, Colditz G. Oral contraceptives and breast cancer. Review and meta-analysis. Cancer 1990; 66: 2253-60.
22. Rushton L, Jones DR. Oral contraceptive use and breast cancer risk: A meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use. Br. J. Obstet. Gynaecol. 1992; 99: 239-46.
23. Wong IL, Morris RS, Chang L. A prospective randomised trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab. 1995; 80: 233-8.
24. Erenus M, Gurbuz O, Durmusoglu F. Comparison of the efficacy of spironolactone vs flutamide in the treatment of hirsutism. Fertil. Steril. 1994; 61: 613-16.
25. Wagner BM. Long term studies of spironolactone in animals and comparison with potassium canrenoate. J. Drug Develop. 1987; 1: S7-11.
26. Barker DJP. The epidemiological evidence relating to spironolactone and malignant disease in man. J. Drug Develop. 1987; 1: S22-5.
27. Loube SD, Quirck RA. Breast cancer associated with administration of spironolactone. Lancet 1975; i: 1428-9.
28. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br. J. Dermatol. 1985; 112: 124-5.
29. Shaw JC. Spironolactone in dermatological therapy. J. Am. Acad. Dermatol. 1991; 24: 236-43.
30. Cusan L, Dupont A, Gomez JL. Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomised controlled trial. Fertil. Steril. 1994; 61: 281-7.
31. Muhlemann MF, Carter GD, Cream JJ. Oral spironolactone: An effective treatment for acne vulgaris in women. Br. J. Dermatol. 1986; 115: 227-32.
32. Shaw JC. Antiandrogen and hormonal treatment of acne. Dermatol. Clin. 1996; 14: 803-11.
33. Erenus M, Yucelten D, Gurbuz O. Comparison of spironolactone-oral contraceptive vs cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil. Steril. 1996; 66: 216-19.
34. Hammerstein J, Meckies J, Leo-Rossberg I. Use of cyproterone acetate in the treatment of acne, hirsutism and virilism. J. Steroid Biochem. Mol. Biol. 1975; 6: 827-36.
35. Grigoriou O, Papadias C, Konidaris S. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: A randomised controlled trial. Gynecol Endocrinol. 1996; 10: 119-23.
36. Van Wayjen RG, Van den Ende A. Experience in the long term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: Efficacy, metabolic and endocrine effects. Exp. Clin. Endocrinol. 1995; 103: 241-51.
37. Hirsch D, Kovatz S, Berneim J. Fatal fulminant hepatitis from cyproterone acetate. Isr. J. Med. Sci. 1994; 30: 238-40.
38. Levesque H, Manchon ND, Moore N. Fulminant hepatitis due to cyproterone acetate. Lancet 1989; i: 215-16.
39. Rudiger T, Beckman J, Queber W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyl-oestradiol. Lancet 1995; 345: 452-3.
40. Watanabe S, Yamasaki S, Tanae A. Three cases of hepatocellular carcinoma among cyproterone users. Lancet 1994; 344: 1567-8.
41. Barth H, Cherry CA, Wojnarowska F. Cyproterone acetate for severe hirsutism: Results of a double-blind dose-ranging study. J. Clin. Endocrinol. 1991; 35: 5-10.
42. Marugo M, Bernasconi D, Meozzi M. The use of flutamide in the management of hirsutism. J. Endocrinol. Invest. 1994; 17: 195-9.
43. Fruzzetti F, De Lorenzo D, Ricci C. Clinical and endocrine effects of flutamide in hyperandrogenic women. Fertil. Steril. 1993; 60: 806-13.
44. Cusan L, Dupont A, Belanger A. Treatment of hirsutism with the pure antiandrogen flutamide. J. Am. Acad. Dermatol. 1990; 23: 462-9.
45. Marcondes JAM, Minnani SL, Luthold WW. Treatment of hirsutism in women with flutamide. Fertil. Steril. 1992; 57: 543-7.
46. Motta T, Maggi J, Azzolari E. Flutamide in the treatment of hirsutism. Int. J. Gynaecol. Obstet. 1991; 32: 155-7.
47. Muderris H, Bayram F, Sahin Y. The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertil. Steril. 1996; 66: 220-2.
48. Moghetti P, Castello R, Negri C. Flutamide in the treatment of hirsutism: Long-term clinical effects, endocrine changes, and androgen receptor behaviour. Fertil. Steril. 1995; 64: 511-17.
49. Cesur V, Hamel N, Uysal AR. The use of antiandrogen flutamide in the treatment of hirsutism. Endocrinology 1994; 41: 573-7.
50. Miller JA, Wojnarowska FT, Dowd PM. Antiandrogen treatment in women with acne: A controlled trial. Br. J. Dermatol. 1986; 114: 705-16.
51. Cusan L, Dupont A, Gomez JL. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am. J. Med. 1992; 92: 465-70.
52. Wysowski DK, Freiman JP, Tourtelot JB. Fatal and non-fatal hepatotoxicity associated with flutamide. Ann. Intern. Med. 1993; 118: 860-4.
53. Wallace C, Lalor EA, Chik CL. Hepatotoxicity complicating flutamide treatment of hirsutism. Ann. Intern. Med. 1993; 119: 1150.
54. Castelo-Branco C, Martinez de Osaba MJ, Martinez S. Effects of a long acting gonadotrophin releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. Metabolism 1996; 45: 24-7.
55. Couzinet B, Le Strat N, Brailly S. Comparative effect of cyproterone acetate and a long acting gonadotrophin releasing hormone agonist in polycystic ovarian disease. J. Endocrinol. Metab. 1986; 63: 1031-5.
56. Steingold K, de Zeigler D, Cedars M. Clinical and hormonal effects of chronic gonadotrophin releasing hormone agonist in polycystic ovarian disease. J. Exp. Clin. Endocrinol. 1995; 104: 115-19.
57. Bertoli A, Fusco A, Magnani A. Efficacy of low dose GNrH analogue (buserelin) in the treatment of hirsutism. J. Exp. Clin. Endocrinol. 1995; 103: 15-20.
58. Faloia E, Filipponi S, Mancini V. Treatment with gonadotrophin releasing hormone agonist in acne or idiopathic hirsutism. J. Endocrinol. Invest. 1993; 16: 675-7.
59. Ciotta L, Cianci A, Giuffrida G. Clinical and hormonal effects of gonadotrophin releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. Fertil. Steril. 1996; 65: 61-7.
60. Rittmaster RS. Finasteride. N. Engl. J. Med. 1994; 330: 120-5.
61. Gormley GJ, Stoner E, Bruskewitz RC. The effect of finasteride on men with benign prostatic hyperplasia. N. Engl. J. Med. 1992; 327: 1185-91.
62. Ciotta L, Cianci A, Calogero AE. Clinical and endocrine effects of finasteride, a 5-α reductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril. 1995; 64: 299-306.
63. Fruzzetti F, de Lorenzo D, Parrini D. Effects of finasteride, a 5-α reductase inhibitor, on circulating androgens and gonadotrophin secretion in hirsute women. J. Clin. Endocrinol. Metab. 1994; 79: 831-5.
64. Carmina E, Lobo RA. Peripheral androgen blockade vs glandular androgen suppression in the treatment of hirsutism. J. Obstet. Gynaecol. 1991; 78: 845-9.
65. Rittmaster RS, Givner ML. Effect of daily and alternate day low dose prednisone on serum cortisol and adrenal androgens in hirsute women. J. Clin. Endocrinol. Metab. 1988; 67: 400-3.
66. Loughlin T, Cunningham S, Moore A. Adrenal abnormalities in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1986; 62: 142-7.